![Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia | Hypertension Research Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia | Hypertension Research](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41440-019-0308-5/MediaObjects/41440_2019_308_Fig1_HTML.png)
Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia | Hypertension Research
![Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Recommendation Statement | AAFP Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Recommendation Statement | AAFP](https://www.aafp.org/content/dam/brand/aafp/pubs/afp/issues/2017/0115/od1-t2.gif)
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Recommendation Statement | AAFP
![The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms - Cooper‐DeHoff - 2022 - Clinical Pharmacology & Therapeutics - Wiley Online Library The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms - Cooper‐DeHoff - 2022 - Clinical Pharmacology & Therapeutics - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/c413d806-8bd7-447e-b2a0-b0ed5f81e2d7/cpt2557-fig-0001-m.jpg)
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms - Cooper‐DeHoff - 2022 - Clinical Pharmacology & Therapeutics - Wiley Online Library
![High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better - Mayo Clinic Proceedings High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better - Mayo Clinic Proceedings](https://www.mayoclinicproceedings.org/cms/asset/99073c92-32cd-40e3-94ff-311c2dced337/gr1.jpg)
High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better - Mayo Clinic Proceedings
![Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis - ScienceDirect Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2352187221004095-gr2.jpg)
Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis - ScienceDirect
![PDF] Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. | Semantic Scholar PDF] Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8069b1c2d8623a8041c32b6cbf235ab2f95be264/2-Table1-1.png)
PDF] Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. | Semantic Scholar
![Abstract 15453: Are High Intensity Statins Beneficial in Patients With “High Intensity Like” LDL-C Reduction on Low Dose Statin: Insights From the TNT Trial | Circulation Abstract 15453: Are High Intensity Statins Beneficial in Patients With “High Intensity Like” LDL-C Reduction on Low Dose Statin: Insights From the TNT Trial | Circulation](https://www.ahajournals.org/cms/asset/5f31503a-e0b4-42b5-9679-86f3565b5e93/g15453.jpg)
Abstract 15453: Are High Intensity Statins Beneficial in Patients With “High Intensity Like” LDL-C Reduction on Low Dose Statin: Insights From the TNT Trial | Circulation
![IJMS | Free Full-Text | Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter? IJMS | Free Full-Text | Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?](https://www.mdpi.com/ijms/ijms-23-09326/article_deploy/html/images/ijms-23-09326-g003.png)